Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dithiodesmethyl carbodenafil is a synthetic small molecule analogue of sildenafil (Viagra) that acts as a phosphodiesterase-5 (PDE-5) inhibitor. It is not an approved pharmaceutical drug but is frequently identified as an undeclared illegal adulterant in dietary supplements marketed for male sexual enhancement. Structurally, it features a thiocarbonyl-thiolactam skeleton and shares the same pharmacological mechanism as approved PDE-5 inhibitors, which involves increasing cyclic guanosine monophosphate (cGMP) levels to promote smooth muscle relaxation and increased blood flow to the corpus cavernosum. Its presence in supplements poses significant health risks, particularly the potential for life-threatening hypotension when combined with nitrates. The FDA has issued multiple warnings and recalls for products containing this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dithiodesmethyl carbodenafil.